

6th IAS Conference on HIV Pathogenesis, Treatment and Prevention

Roadmap of HIV/TB Sessions

HIV/TB Research meeting in conjunction with the 6th conference on HIV Pathogenesis, Treatment and Prevention

Time: Sunday 17th July, 12:30 – 16:00

Venue: Grand Hotel Ritz Rome, Via Chelini 14, Rome

[Link to meeting report and presentations](#)

The objective of this meeting will be to promote high level scientific interchange of ideas and research priorities related to the development of new and novel anti-TB drugs for people living with HIV, and issues around the prevention, diagnostic, care and treatment of HIV-related TB in children. The meeting will share new data from ongoing studies and discuss potential implementation, discuss controversial issues and identify critical research questions. By invitation only.

Organized by the World Health Organization and the Global TB/HIV Working Group, in collaboration with the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE).

For more information please contact: tbhiv@who.int

THE IAS CONFERENCE SUNDAY, 17 July 2011

The Role of Communities in the Elimination of Pediatric HIV and AIDS - Bringing Program Implementers and Researchers Together

Non-commercial Satellite Session - SUSA03

Time: 10:15 – 12:15 Venue: Mini Room 2

10:40: TB Defaulter Tracing in an Informal Settlement in South Africa: The Communities Role in Identifying Households, presented by Ima Chima, South Africa.

MONDAY, 18 JULY 2011

HIV and Co-Infections: HCV, Malaria, TB and Beyond

Bridging session – [MOBS01](#)

Time: 14:25 - 16:00 Venue: Session Room 1

14:25: IAS TB/HIV Research prize will be presented to Sabine Margot Hermans, the Netherlands by Elly Katabira, Uganda and Papa Salif Sow, Senegal

14:35: HIV and TB, presented by Alberto Matteelli, Italy.

Diagnostics: Innovation, Cost-Effectiveness and Scale-Up

Oral Abstract Session - [MOAD01](#)

Time: 16:30 - 18:00 Venue: Session Room3

16:40: [MOAD0102](#): Cost-effectiveness of Xpert MTB/RIF for screening for tuberculosis prior to antiretroviral therapy in South Africa, presented by Jason R Andrews, USA.

TUESDAY, 19 JULY 2011

Building Global HIV/AIDS Clinical Pharmacology Research Capacity

Non-commercial Satellite Session – TUSA01

Time: 07:00 - 08:30 Venue: Mini Room 1

07:05: HIV and TB: capacity challenges to the use of current drugs and developing new drugs, Presented by Kimberly Scarsi, USA.

Comparison of progress in provision of HIV testing and ART for TB patients - African region, the rest of the world and PEPFAR supported countries

Poster Presentation - [TUPE485](#)


Time: 12:30 – 14:30 Venue: Poster exhibition area

For other abstracts visit IAS website: <http://pag.ias2011.org/PosterExhibition.aspx>

The TB/HIV Working Group of the Stop TB Partnership

Housed in the Stop TB Department of WHO

Visit our website http://www.stopTB.org/wg/tb_hiv/default.asp and become a member or keep up to date with TB/HIV issues by connecting with our Facebook page or following us on Twitter.



TIME TO ACT – SAVE A MILLION LIVES BY 2015

Prevent and treat TB among people living with HIV

Other Tuberculosis Related Poster Discussions:

- [WEPDB0201](#): Lack of identification of adult TB contacts in infants with microbiologically confirmed or clinically presumed TB (MCCP TB) in clinical trial P1041, S Nachman et al
- [WEPDB0202](#): Causes of death and risk factors of mortality in HIV-infected patients treated for tuberculosis enrolled in the CAMELIA trial, O. Marcy et al.
- [WEPDB0203](#): Prevalence of multi-drug resistant mycobacterium tuberculosis (MDRTB) among patients admitted to the Bwaila-Kamuzu Central Hospital (KCH) inpatient tuberculosis ward, Lilongwe, Malawi, C.K. Vorkas et al
- [WEPDB0204](#): CD4-specific rates of death and tuberculosis among HIV-infected adults prior to antiretroviral treatment with high CD4 counts in West Africa, C. Lewden et al
- [WEPDB0205](#): Risk of tuberculosis following HIV seroconversion in low-burden tuberculosis countries, S Lodi, et al
- [WEPDB0206](#): High prevalence of subclinical tuberculosis in HIV-1 infected persons without advanced immunodeficiency: implications for TB screening, T Oni et al.

WEDNESDAY, 20 JULY 2011

The TB Paradox

Oral Abstract Session WEAX01: [WEAX0102](#), [WEAX0103](#), [WEAX0104](#), [WEAX0105](#)
Time: 11:00 - 12:30 Venue: Session Room 2

The Impact of the Economic Crisis on HIV Programmes: Is Integration of Services and Operational Research the Solution?

Symposium – WESY02
Time: 11:00 - 12:30 Venue: Session Room 3

The session will examine solutions to the detrimental impact of the current economic crisis which threatens sustainability of funding for HIV programmes, discuss how efficiency gains facilitated by better integration of HIV programmes with other MDG-related programmes and health systems strengthening are part of the solution, and advocate further scaling up of resources in addition to these efficiency gains for reaching universal access by 2015.

The Integration Imperative: HIV Services and Health Systems

Oral Poster Discussion – WEPDD01
Time: 13:00 - 14:00 Venue: Mini Room 1

13:05: [WEPDD0102](#): Increasing access to HIV counselling and testing (HCT), providing early detection and access to care: a community HCT model for integrated HIV and TB testing in Cape Town, South Africa, presented by Sue-Ann Meehan, South Africa.

13:10: [WEPDD0103](#): Integration of HIV and TB services results in earlier and more prioritised ART initiation in Uganda, presented by Sabine Margot Hermans, Uganda.

TB and Only TB

Oral Poster Discussion – [WEPDB02](#)
Time: 13:00 - 14:00 Venue: Mini Room 4

Late Breaker Cross-Track A/B

Oral Abstract Session – WELBX
Time: 14:30 - 16:00 Venue: Session Room 3

15:10: [WELBX05](#): Results of the CARINEMO-ANRS 12146 randomized trial comparing the efficacy and safety of nevirapine versus efavirenz for treatment of HIV-TB co-infected patients in Mozambique, presented by Maryline Bonnet, Switzerland.

Late Breaker Track B

Oral Abstract Session – WELBB
Time: 16:30 - 17:30 Venue: Session Room 1

16:40: [WELBB02](#): Impact of tuberculosis (TB) screening and isoniazid preventive therapy (IPT) on incidence of TB and death in the TB/HIV in Rio de Janeiro (THRio) study, presented by Valeria Saraceni, Brazil.

Late Breaker Track D

Oral Abstract Session – WELBD
Time: 16:30 - 17:30 Venue: Session Room 3

16:30: [WELBD01](#): Taking the first steps in national GeneXpert implementation: lessons learned from South Africa, presented by Wendy Stevens, South Africa.

The TB/HIV Working Group of the Stop TB Partnership
Housed in the Stop TB Department of WHO

Visit our website http://www.stoptb.org/wg/tb_hiv/default.asp and become a member or keep up to date with TB/HIV issues by connecting with our Facebook page or following us on Twitter.

